💊Pharmacology💊 - Diabetes Flashcards

1
Q

What is the correct series of therapeutic steps when prescribing medications?

A
  1. Identify the patients problem
  2. Specify the therapeutic objective
  3. Select a drug on the bases of comparative efficacy, safety, cost and suitability
  4. Discuss choice of medication with patient(/carer) and make shared decision
  5. Write a correct prescription
  6. Counsel the patient on appropriate use of the medication
  7. Make appropriate arrangements for follow up
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the diagnostic options for investigations for diabetes?

A

Blood tests:
HbA1c
Fasting glucose
Random glucose
Postprandial glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What problems does this woman have?
A 72 year old woman, Mrs Wallace, attends a GP appointment for a routine health check. Her BMI is 31, her blood pressure is 144/92mmHg, and a brief history reveals her mother dies of diabetes, although Mrs Wallace reports no polyuria, polydipsia or weight loss. Her GP a routine NHS health check. During a follow up appointment, Mrs Wallace’s blood tests reveal the following: HbA1c is 65 mmol/mol, LDL-cholesterol 5.18 mmol/L, HDL-cholesterol 0.8 mmol/L, and triglycerides 6.53 mmol/L. Urinalysis shows glycosuria but no ketones. Her blood pressure is 148/91HHmg. A further appointment confirmed the elevated HbA1c.

A

Type 2 diabetes
Dyslipidemia
Hypertension
High BMI
All risk factors for CVD
All largely asymptomatic - T2DM is quite insidious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the normal thresholds for HbA1c, HDL, LDL, triglycerides?

A

HbA1c threshold for diagnosis is 48
HDL >1mmol/L
LDL <2.6mmol/L
Triglycerides <1.7mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the therapeutic objectives for Mrs Wallace? (high BMI, blood glucose+HbA1c, dyslipidemia, hypertension)

A

Lower BMI
Lower HbA1c
Improve lipid profile
Lower blood pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the first step of T2DM management?

A

Standard release Metformin (500mg/day, oral)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the first intensification of T2DM management?

A

If HbA1c rises to 58mmol/mol:
Consider dual therapy of metformin with 1 of the following:
DPP-4 inhibitor
Pioglizatone
SU (sulphonylurea)
SGLT-2 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the second intensification of T2DM management?

A

If HbA1c rises to 58mmol/mol, and first intensification has insufficient effect:
Insulin based treatment
OR
Triple therapy:
Metformin, DPP-4 inhibitor, SU
Metformin, Pioglitazone, SU
Metformin, Pioglitazone/SU, SGLT-2 inhibitor
Support patient to aim for HbA1c of 53

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mrs Wallace visits her GP for the firsts time about her T2DM, what treatment should she receive?

A

Standard release Metformin (500mg/day, oral)
Despite her HbA1c, she is the first line treatment as this is her first attempt at treatment, therefore would be inappropriate to go down a route of treatment which serves as an “intensification” at this point

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What consequences does the molecular structure of metformin have on its absorption?

A

Has a pKa of 12.4
Meaning even in the most alkaline of tissue, will be in its charged form
Not easily absorbed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How is metformin absorbed, if it is in its charged form in all tissues?

A

Active transport protein
Organic cation transporter (OCT-1) is expressed in hepatocytes, enterocytes and proximal tubules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why are the locations of the OCT-1 transporters significant for the pharmacokinetics of metformin?

A

Action of metformin: Liver is site of action (inhibits hepatic gluconeogenesis), OCT-1 enhances distribution to the liver
Absorption of metformin: metformin is absorbed in the small bowel after being taken orally
Elimination of metformin: OCT-1 transporters in proximal tubules allow transport into renal cells, and then excretion into the filtrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What side effects are patients vulnerable to with DPP-4 inhibitors?

A

Upper respiratory tract infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What side effects are patients vulnerable to with Pioglitazone?

A

Heart failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What side effects are patients vulnerable to with Sulphonylurea?

A

Weight gain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What side effects are patients vulnerable to with SGLT-2 inhibitors?

A

Urogenital infections

17
Q

What is the primary drug target (and its type) of Metformin?

A

AMP activated protein kinase (enzyme)

18
Q

What is the primary drug target (and its type) of DPP-4 inhibitors?

A

Dipeptidyl peptidase-4 (DPP-4) (enzyme)

19
Q

What is the primary drug target (and its type) of Sulphonylureas?

A

ATP-sensitive K+ channels (ion channels)

20
Q

What is the primary drug target (and its type) of SGLT-2 inhibitors?

A

Sodium-glucose co-transporter-2 (transport protein)

21
Q

Where is the location of action of Metformin?

A

Hepatocyte mitochondria

22
Q

Where is the location of action of DPP-4 inhibitors?

A

Vascular endothelium

23
Q

Where is the location of action of Sulphonylureas?

A

Pancreatic beta cells

24
Q

Where is the location of action of SGLT-2 inhibitors?

A

Proximal convoluted tubule

25
Q

What is the action of Metformin?

A

Decreased gluconeogenesis

26
Q

What is the action of DPP-4 inhibitors?

A

Increased plasma incretin levels

27
Q

What is the action of Sulphonylureas?

A

Stimulates insulin secretion

28
Q

What is the action of SGLT-2 inhibitors?

A

Decreased glucose reabsorption

29
Q

What is DKA?

A

Diabetic ketoacidosis - liver makes ketones due to lack of intracellular glucose - makes ketones as alternative food source - leads to acidosis

30
Q

What is the series of events that leads to DKA?

A

Liver cells are surrounded by glucose that is unable to enter cells because of lack of insulin, so ketones are made as an alternative energy source, leading to acidosis

31
Q

Function of which system must always be monitored in a patient showing signs of impairment whilst on metformin?

A

Renal system

32
Q

What is a healthy eGFR for a patient taking metformin (i.e. no adjustment needed)?

A

eGFR of >60

33
Q

What is advised for a patient on metformin whose eGFR is sat between 45 and 60?

A

Monitor eGFR
Redo renal function test in 3-6 months
No adjustment needed immediately

34
Q

What is advised if a patient has an eGFR of 30-45, re. metformin?

A

If already on metformin, consider 50% dose decrease
If not on metformin, do NOT newly initiate

35
Q

What is the significance of a patient with an eGFR of less than 30 on their metformin treatment?

A

Contraindicated
Do NOT initiate metformin treatment
STOP any current metformin treatment